

(43) International Publication Date
21 September 2017 (21.09.2017)(51) International Patent Classification:
A61K 47/00 (2006.01) *C07K 16/30* (2006.01)
A61K 47/55 (2017.01)(21) International Application Number:
PCT/US2017/022541(22) International Filing Date:
15 March 2017 (15.03.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/308,639 15 March 2016 (15.03.2016) US
62/317,792 4 April 2016 (04.04.2016) US
62/367,510 27 July 2016 (27.07.2016) US(71) Applicant: SEATTLE GENETICS, INC. [US/US];
21823 30th Drive SE, Bothell, Washington 98021 (US).

(72) Inventors: SUSSMAN, Django; 21823 30th Drive SE, Bothell, Washington 98021 (US). LI, Fu; 21823 30th Drive SE, Bothell, Washington 98021 (US). KOSTIC, Ana; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(74) Agents: KELLY, Beth L. et al.; 21823 30th Drive SE, Bothell, Washington 98021 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: COMBINATION THERAPY USING A LIV1-ADC AND A CHEMOTHERAPEUTIC




FIGURE 6

(57) Abstract: The invention provides methods of treating a subject having or at risk of cancer by administering a LIV-1 antibody drug conjugate and a chemotherapeutic.

COMBINATION THERAPY USING A LIV1-ADC AND A CHEMOTHERAPEUTIC

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62/308,639 filed March 15, 2016, U.S. Provisional Application No. 62/317,792 filed April 4, 2016, and U.S. Provisional Application No. 62/367,510 filed July 27, 2016, the disclosures of which are incorporated by reference herein in their entirety for all purposes.

REFERENCE TO A SEQUENCE LISTING

[0002] A sequence listing designated 0710-00313PC Sequence Listing ST25.txt of 16 KB created March 1, 2017, is incorporated herein by reference.

FIELD OF THE INVENTION

[0003] This invention relates to methods for the treatment of cancer comprising administering a LIV1-ADC and a chemotherapeutic.

BACKGROUND

[0004] LIV-1 is a member of the LZT (LIV-1-ZIP Zinc Transporters) subfamily of zinc transporter proteins. Taylor et al., *Biochim. Biophys. Acta* 1611:16-30 (2003). Computer analysis of the LIV-1 protein reveals a potential metalloprotease motif, fitting the consensus sequence for the catalytic zinc-binding site motif of the zinc metalloprotease. LIV-1 mRNA is primarily expressed in breast, prostate, pituitary gland and brain tissue.

[0005] The LIV-1 protein has also been implicated in certain cancerous conditions, e.g. breast cancer and prostate cancer. The detection of LIV-1 is associated with estrogen receptor-positive breast cancer, McClelland et al., *Br. J. Cancer* 77:1653-1656 (1998), and the metastatic spread of these cancers to the regional lymph nodes. Manning et al., *Eur. J. Cancer* 30A:675-678 (1994).

[0006] SGN-LIV1A is a LIV-1-directed antibody-drug conjugate (ADC) consisting of three components: 1) the humanized antibody hLIV22, specific for human LIV-1, 2) the microtubule disrupting agent monomethyl auristatin E (MMAE), and 3) a stable linker, valine-citrulline (vc), that covalently attaches MMAE to hLIV22. The proposed mechanism of action (MOA) is initiated by SGN-LIV1A binding to LIV-1 on the cell surface followed by internalization of the ADC. Upon trafficking to lysosomes, the delivered drug (MMAE) is released through proteolytic degradation of the vc linker. Binding of the released drug to tubulin disrupts the microtubule network, leading to cell cycle arrest and apoptosis.

[0007] SGN-LIV1A has been shown to reduce tumor volumes in vivo, and is currently being evaluated in a phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer. However, improvements are needed in cancer therapy. The present invention solves this and other problems.

SUMMARY OF THE CLAIMED INVENTION

[0008] The invention provides a method for treating a subject having or at risk of cancer. The method includes administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and a chemotherapeutic. The LIV-1-ADC includes a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E), and the chemotherapeutic is one of carboplatin, doxorubicin, paclitaxel, trastuzumab, and an mTOR inhibitor. Optionally, the subject has prostate cancer, ovarian cancer, endometrial cancer, pancreatic cancer, lung cancer, a cervical cancer, a melanoma, squamous cell carcinoma, or a breast cancer, such as triple negative breast cancer, triple positive breast cancer, HER2-positive breast cancer, or hormone receptor positive breast cancer.

[0009] In some embodiments, the LIV-1-ADC is administered at a dosage between 1.5 mg/kg and 4 mg/kg of the subject's body weight. In an embodiment, the LIV-1-ADC is administered at a dosage of 2.5 mg/kg of the subject's body weight. In an embodiment, the LIV-1-ADC is administered once every 3 weeks. In an embodiment, the LIV-1-ADC is administered by intravenous injection.

[0010] In an embodiment, the chemotherapeutic is carboplatin, and is administered at a dosage between 200 mg/m² and 750 mg/m². In an embodiment, the carboplatin is administered by intravenous injection. In another embodiment, the chemotherapeutic is doxorubicin, and is administered at a dosage between 40 mg/m² and 80 mg/m². In an embodiment, the doxorubicin is administered by intravenous injection. In another embodiment, the chemotherapeutic is paclitaxel, and is administered at a dosage between 100 mg/m² to 260 mg/m². In an embodiment, the paclitaxel is administered by intravenous injection.

[0011] The invention also provides methods for treating a subject having or at risk of cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and either trastuzumab emtansine or pertuzumab. The LIV-1-ADC includes a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E).

BRIEF DESCRIPTION OF THE FIGURES

[0012] **Figure 1** shows the viability of multiple agents on MCF-7 cells, according to an embodiment of the invention.

[0013] **Figure 2** shows the effect of SGN-LIV1A and doxorubicin on MCF-7 cells, according to an embodiment of the invention.

[0014] **Figure 3** shows the effect of SGN-LIV1A and paclitaxel on MCF-7 cells, according to an embodiment of the invention.

[0015] **Figure 4** shows the effect of SGN-LIV1A and gemcitabine on MCF-7 cells, according to an embodiment of the invention.

[0016] **Figure 5** shows the effect of SGN-LIV1A and everolimus on MCF-7 cells, according to an embodiment of the invention.

[0017] **Figure 6** shows the effects of SGN-LIV1A and either doxorubicin (left) or Abraxane (nab-paclitaxel) (right) on tumor growth in NOD Scid Gamma (NSG) mice, according to an embodiment of the invention.

[0018] **Figure 7** shows the effects of SGN-LIV1A and either carboplatin (left) or cyclophosphamide (right) on tumor growth in NOD Scid Gamma (NSG) mice, according to an embodiment of the invention.

[0019] **Figure 8** shows the effects of SGN-LIV1A and either gemcitabine (left) or paclitaxel (right) on tumor growth in NOD Scid Gamma (NSG) mice, according to an embodiment of the invention.

DEFINITIONS

[0020] The term “antibody” includes intact antibodies and binding fragments thereof. Typically, antibody fragments compete with the intact antibody from which they were derived for specific binding to the target including separate heavy chains, light chains Fab, Fab', F(ab')₂, F(ab)c, diabodies, Dabs, nanobodies, and Fv. Fragments can be produced by recombinant DNA techniques, or by enzymatic or chemical separation of intact immunoglobulins. The term “antibody” also includes a diabody (homodimeric Fv fragment) or a minibody (V_L-V_H-C_H3), a bispecific antibody or the like. A bispecific or bifunctional antibody is an artificial hybrid antibody having two different heavy/light chain pairs and two different binding sites (see, *e.g.*, Songsivilai and Lachmann, *Clin. Exp. Immunol.*, 79:315-321 (1990); Kostelny et al., *J. Immunol.*, 148:1547-53 (1992)). The term “antibody” includes an antibody by itself (naked antibody) or an antibody conjugated to a cytotoxic or cytostatic drug.

[0021] A “cytotoxic effect” refers to the depletion, elimination and/or the killing of a target cell. A “cytotoxic agent” refers to an agent that has a cytotoxic effect on a cell. Cytotoxic agents can be conjugated to an antibody or administered in combination with an antibody.

[0022] A “cytostatic effect” refers to the inhibition of cell proliferation. A “cytostatic agent” refers to an agent that has a cytostatic effect on a cell, thereby inhibiting the growth and/or expansion of a specific subset of cells. Cytostatic agents can be conjugated to an antibody or administered in combination with an antibody.

[0023] The term “pharmaceutically acceptable” as used herein refers to those compounds, materials, compositions, and/or dosage forms that are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio. The term “pharmaceutically compatible ingredient” refers to a pharmaceutically acceptable diluent, adjuvant, excipient, or vehicle with which an anti-LIV-1 antibody is administered.

[0024] The phrase “pharmaceutically acceptable salt,” refers to pharmaceutically acceptable organic or inorganic salts of an anti-LIV-1 antibody or conjugate thereof or agent administered with an anti-LIV-1 antibody. Exemplary salts include sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p toluenesulfonate, and pamoate (i.e., 1,1' methylene bis -(2 hydroxy 3 naphthoate)) salts. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Multiple counter ions may occur in instances where multiple charged atoms are part of the pharmaceutically acceptable salt. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterion.

[0025] The term “effective amount” refers to the amount of a LIV-1-ADC, e.g., SGN-LIV1A, that is sufficient to inhibit the occurrence or ameliorate one or more clinical or diagnostic symptoms of a LIV-1-associated disorder in a subject. An effective amount of an agent is administered according to the methods described herein in an “effective regimen.” The term “effective regimen” refers to a combination of amount of the agent and dosage frequency adequate to maintain high LIV-1 occupancy, which may accomplish treatment or prevention of a LIV-1-associated disorder. In a preferred

embodiment, an effective regimen maintains near complete, e.g., greater than 90%, LIV-1 occupancy on LIV-1-expressing cells during dosing intervals.

[0026] The terms “treatment” and “therapy,” and the like, as used herein, are meant to include therapeutic or suppressive measures for a disease or disorder leading to any clinically desirable or beneficial effect, including, but not limited to, alleviation or relief of one or more symptoms, regression, slowing or cessation of progression of the disease or disorder. For example, treatment can include a decrease or elimination of a clinical or diagnostic symptom of a LIV-1-expressing disorder after the onset of the clinical or diagnostic symptom by administration of an anti- LIV-1 antibody or other LIV-1 binding agent to a subject. Treatment can be evidenced as a decrease in the severity of a symptom, the number of symptoms, or frequency of relapse.

[0027] Except when noted, the terms "subject" or "patient" are used interchangeably and refer to mammals such as human patients and non-human primates, as well as experimental animals such as rabbits, dogs, cats, rats, mice, and other animals. Accordingly, the term "subject" or "patient" as used herein means any mammalian patient or subject to which the LIV-1 binding agents of the invention can be administered. In preferred embodiments, the terms subject or patient are used to refer to human patients. Subjects of the present invention include those that have been diagnosed with a LIV-1 expressing cancer, including, for example, breast cancer, prostate cancer, ovarian cancer, endometrial cancer, pancreatic cancer, lung cancer, cervical cancer, a melanoma, or squamous cell carcinoma. In certain embodiments, the subject will have a refractory or relapsed LIV-1 expressing cancer.

[0028] Compositions or methods “comprising” one or more recited elements may include other elements not specifically recited. For example, a composition that comprises antibody may contain the antibody alone or in combination with other ingredients.

[0029] Designation of a range of values includes all integers within or defining the range.

[0030] As used herein, the term "about" denotes an approximate range of plus or minus 10% from a specified value. For instance, the language "about 20%" encompasses a range

of 18-22%. As used herein, about also includes the exact amount. Hence, "about 20%" means "about 20%" and also "20%".

DETAILED DESCRIPTION


I. General

[0031] The invention provides methods for treating cancer, in particular breast cancer. The present inventors have discovered that combination therapy with two different classes of anticancer compounds: antibody-drug conjugate compounds and chemotherapeutic agents, can improve a therapeutic benefit for subjects suffering from cancer. In particular, the present inventors have found that combination therapy with (1) an anti-LIV-1 antibody conjugated to an auristatin compound and (2) a chemotherapeutic agent provides synergistic therapeutic effects in the treatment of cancer.

II. LIV-1-ADC

[0032] Unless otherwise indicated, a LIV-1-antibody drug conjugate (LIV-1-ADC) includes an antibody specific for the human LIV-1 protein conjugated to a cytotoxic agent. An exemplary human LIV-1 sequence is assigned Swiss Prot accession number Q13433. Q13433 is included herein as SEQ ID NO:1. Three variant isoforms and one polymorphism are known. A second version of the human LIV-1 protein, accession number AAA96258.2, is included herein as SEQ ID NO:2. Four extracellular domains are bounded by residues 29-325, 377-423, 679-686 and 746-755 of Q13433 respectively.

[0033] SGN-LIV1A is a LIV-1-directed antibody-drug conjugate (ADC) produced by the conjugation of the drug linker vcMMAE (monomethyl auristatin E with a valine-citrulline linker) to the humanized antibody hLIV22. hLIV22 is a humanized form of the mouse BR2-22a antibody, described in US Patent No. 9,228,026. The hLIV22 antibody is essentially the same as BR2-22a within experimental error and contains seven back mutations. Methods of making the hLIV22 antibody are also disclosed in US Patent No. 9,228,026. The amino acid sequence of the light chain variable region of hLIV22 is provided herein as SEQ ID NO: 3. The amino acid sequence of the heavy chain variable region of hLIV22 is provided herein as SEQ ID NO: 4. Synthesis and conjugation of the drug linker vcMMAE (shown below; also referred to as 1006) are further described in US Patent No. 9,228,026 and US Patent Pub. No. 20050238649.



III. Combination therapy of chemotherapeutic agents and LIV-1-ADC

[0034] Cancer can be treated using a combination of SGN-LIV1A and a chemotherapeutic agent. The chemotherapeutic agent is either carboplatin, doxorubicin or paclitaxel, trastuzumab, a checkpoint inhibitor, or an mTOR inhibitor (such as Everolimus). Carboplatin (PARAPLATIN®; Bristol Myers Squibb, New York, NY) is an alkylating agent. Doxorubicin (ADRIAMYCIN®, RUBEX®, DOXIL®, MYOCEL®, or CAELYX®) is an anthracycline antibiotic with antineoplastic activity. Paclitaxel (ABRAXANE®; Celgene, Summit, NJ) is a taxane that inhibits microtubule breakdown. Trastuzumab (HERCEPTIN®; Genentech, South San Francisco, CA) is a monoclonal antibody that binds the HER2 receptor. Examples of checkpoint inhibitors (inhibitors that block immune checkpoints) include antibodies such as anti-PD-1 antibodies (e.g., MEDI0680, AMP-224, nivolumab, pembrolizumab, and pidilizumab), anti-PD-L1 antibodies (e.g., MEDI4736 and MPDL3280A), and anti-CTLA4 antibodies (e.g., ipilimumab and tremelimumab). Other checkpoint inhibitors/activators include B7-DC-Fc, LAG3 and TIM3.

[0035] The combination of SGN-LIV1A and a chemotherapeutic agent can be given to subjects at levels that inhibit cancer cell growth, while at the same time are tolerated by the subject. In an embodiment, administration of the combination decreases the toxic effects caused by administration of a chemotherapeutic agent alone. In some embodiments, the combination of SGN-LIV1A and a chemotherapeutic agent is synergistic or additive. For some combinations, each agent in the combination can be effectively administered at lower levels than when administered alone.

[0036] As discussed above, the combination therapies of the invention can be used to treat cancer. Some such cancers show detectable levels of LIV-1 measured at either the

protein (e.g., by immunoassay using one of the exemplified antibodies) or mRNA level. Some such cancers show elevated levels of LIV-1 relative to noncancerous tissue of the same type, preferably from the same patient. An exemplary level of LIV-1 on cancer cells amenable to treatment is 5000-150000 LIV-1 molecules per cell, although higher or lower levels can be treated. Optionally, a level of LIV-1 in a cancer is measured before performing treatment.

[0037] Examples of cancers associated with LIV-1 expression and amenable to treatment with the combination therapies of the invention include breast cancer, prostate cancer, ovarian cancer, endometrial cancer, pancreatic cancer, cervical, liver, gastric, kidney, and squamous cell carcinomas (e.g., bladder, head, neck and lung), skin cancers, e.g., melanoma, small lung cell carcinoma or lung carcinoid. The treatment can be applied to patients having primary or metastatic tumors of these kinds. The treatment can also be applied to patients who are refractory to conventional treatments (e.g., for breast cancer: hormones, tamoxifen, HERCEPTIN®), or who have relapsed following a response to such treatments. The methods can also be used on triple negative breast cancers. A triple negative breast cancer is a term of art for a cancer lacking detectable estrogen and progesterone receptors and lacking overexpression of HER2/neu when stained with an antibody to any of these receptors, such as described in the examples. The methods can also be used on triple positive breast cancers, hormone receptor positive breast cancers, and HER2 positive breast cancers. Staining can be performed relative to an irrelevant control antibody and lack of expression shown from a background level of staining the same or similar to that of the control within experimental error. Likewise, lack of overexpression is shown by staining at the same or similar level within experimental error of noncancerous breast tissue, preferably obtained from the same patient. Alternatively or additionally, triple negative breast cancers are characterized by lack of responsiveness to hormones interacting with these receptors, aggressive behavior and a distinct pattern of metastasis.

[0038] In some embodiments, SGN-LIV1A and a chemotherapeutic agent are administered in such a way that the combination provides a synergistic or additive effect in the treatment of LIV-1-associated cancer in a patient. Administration can be by any suitable means provided that the administration provides the desired therapeutic effect. In

preferred embodiments, SGN-LIV1A and a chemotherapeutic agent are administered during the same cycle of therapy, e.g., during one cycle of therapy, e.g., a three or four week time period.

[0039] SGN-LIV1A and a chemotherapeutic agent are administered in an effective regime meaning a dosage, route of administration and frequency of administration that delays the onset, reduces the severity, inhibits further deterioration, and/or ameliorates at least one sign or symptom of cancer. If a patient is already suffering from cancer, the regime can be referred to as a therapeutically effective regime. If the patient is at elevated risk of the cancer relative to the general population but is not yet experiencing symptoms, the regime can be referred to as a prophylactically effective regime. In some instances, therapeutic or prophylactic efficacy can be observed in an individual patient relative to historical controls or past experience in the same patient. In other instances, therapeutic or prophylactic efficacy can be demonstrated in a preclinical or clinical trial in a population of treated patients relative to a control population of untreated patients.

[0040] Exemplary dosages for SGN-LIV1A are 0.1 mg/kg to 50 mg/kg of the patient's body weight, more typically 1 mg/kg to 30 mg/kg, 1 mg/kg to 20 mg/kg, 1 mg/kg to 15 mg/kg, 1 mg/kg to 12 mg/kg, 1 mg/kg to 10 mg/kg, 2 mg/kg to 30 mg/kg, 2 mg/kg to 20 mg/kg, 2 mg/kg to 15 mg/kg, 2 mg/kg to 12 mg/kg, 2 mg/kg to 10 mg/kg, 3 mg/kg to 30 mg/kg, 3 mg/kg to 20 mg/kg, 3 mg/kg to 15 mg/kg, 3 mg/kg to 12 mg/kg, or 3 mg/kg to 10 mg/kg. In some methods, the patient is administered a dose of at least 1.5 mg/kg, at least 2 mg/kg or at least 3 mg/kg, administered once every three weeks or greater. In an embodiment, the patient is administered a dose of 2.5 mg/kg. In a further embodiment, the patient is administered a dose of 2.5 mg/kg, administered once every three weeks.

The dosage depends on the frequency of administration, condition of the patient and response to prior treatment, if any, whether the treatment is prophylactic or therapeutic and whether the disorder is acute or chronic, among other factors.

[0041] In combination with carboplatin, SGN-LIV1A is administered at a dose between 0.5 mg/kg and 6 mg/kg. Other appropriate dose ranges of SGN-LIV1A in the combination are 1 mg/kg to 5 mg/kg, and 2 mg/kg to 3 mg/kg. In an embodiment, SGN-LIV1A is administered at a dose of 2.5 mg/kg in combination with carboplatin. In combination with SGN-LIV1A, carboplatin is administered at a dose between 100 mg/m²

and 950 mg/m². Other appropriate dose ranges of carboplatin in the combination are 200 mg/m² to 750 mg/m², and 300 mg/m² to 600 mg/m². In an embodiment, carboplatin is administered at a dose of 300 mg/m² in combination with SGN-LIV1A. In another embodiment, carboplatin is administered at a dose of AUC 6 IV in combination with SGN-LIV1A.

[0042] In combination with doxorubicin, SGN-LIV1A is administered at a dose between 0.5 mg/kg and 6 mg/kg. Other appropriate dose ranges of SGN-LIV1A in the combination are 1 mg/kg to 5 mg/kg, and 2 mg/kg to 3 mg/kg. In an embodiment, SGN-LIV1A is administered at a dose of 2.5 mg/kg in combination with doxorubicin. In combination with SGN-LIV1A, doxorubicin is administered at a dose between 30 mg/m² and 90 mg/m². Other appropriate dose ranges of doxorubicin in the combination are 40 mg/m² to 80 mg/m², and 60 mg/m² to 75 mg/m². In an embodiment, doxorubicin is administered at a dose of 60 mg/m² in combination with SGN-LIV1A.

[0043] In combination with paclitaxel, SGN-LIV1A is administered at a dose between 0.5 mg/kg and 6 mg/kg. Other appropriate dose ranges of SGN-LIV1A in the combination are 1 mg/kg to 5 mg/kg, and 2 mg/kg to 3 mg/kg. In an embodiment, SGN-LIV1A is administered at a dose of 2.5 mg/kg in combination with paclitaxel. In combination with SGN-LIV1A, paclitaxel is administered at a dose between 50 mg/m² and 300 mg/m². Other appropriate dose ranges of paclitaxel in the combination are 100 mg/m² to 260 mg/m², and 135 mg/m² to 175 mg/m². In an embodiment, paclitaxel is administered at a dose of 175 mg/m² in combination with SGN-LIV1A. In another embodiment, paclitaxel is administered at a dose of 80 mg/m² in combination with SGN-LIV1A.

[0044] In combination with trastuzumab, SGN-LIV1A is administered at a dose between 0.5 mg/kg and 2.8 mg/kg. In an embodiment, SGN-LIV1A is administered at a dose between 1 mg/kg and 2.8 mg/kg in combination with trastuzumab. In another embodiment, SGN-LIV1A is administered at a dose of 2.5 mg/kg in combination with trastuzumab. In an embodiment, SGN-LIV1A is administered once a week. In another embodiment, SGN-LIV1A is administered once every three weeks. In an embodiment, in combination with SGN-LIV1A, trastuzumab is administered at an initial dose of 8 mg/kg over a 90 minute IV infusion, and then 6 mg/kg over 30-90 minutes of an IV infusion. In

a further embodiment, the 6 mg/kg over 30-90 minutes of an IV infusion is administered every 3 weeks. In a further embodiment, the 6 mg/kg over 30-90 minutes of an IV infusion is administered every 3 weeks for 52 weeks. In another embodiment, in combination with SGN-LIV1A, trastuzumab is administered at an initial dose 4 mg/kg over a 90 minute IV infusion, and then 2 mg/kg over a 30 minute IV infusion. In a further embodiment, the 2 mg/kg over a 30 minute IV infusion is administered once a week. In a further embodiment, the 2 mg/kg over a 30 minute IV infusion is administered once a week for 52 weeks.

[0045] In combination with a checkpoint inhibitor, SGN-LIV1A is administered at a dose between 0.5 mg/kg and 2.8 mg/kg. . In an embodiment, SGN-LIV1A is administered at a dose between 1 mg/kg and 2.8 mg/kg in combination with trastuzumab. In another embodiment, SGN-LIV1A is administered at a dose of 2.5 mg/kg in combination with trastuzumab. In an embodiment, SGN-LIV1A is administered once a week. In another embodiment, SGN-LIV1A is administered once every three weeks.

[0046] Administration of SGN-LIV1A, carboplatin, doxorubicin, paclitaxel, trastuzumab, or an mTOR inhibitor can be parenteral, intravenous, oral, subcutaneous, intra-arterial, intracranial, intrathecal, intraperitoneal, topical, intranasal or intramuscular. In an embodiment, SGN-LIV1A is administered by intraperitoneal injection. In another embodiment, SGN-LIV1A is administered by intravenous injection. In another embodiment, carboplatin is administered by intravenous injection. In another embodiment, paclitaxel is administered by intravenous injection. In another embodiment, doxorubicin is administered by intravenous injection. Administration can also be localized directly into a tumor. Administration into the systemic circulation by intravenous or subcutaneous administration is preferred. Intravenous administration can be, for example, by infusion over a period such as 30-90 min or by a single bolus injection.

[0047] The frequency of administration of each agent of the combination (SGN-LIV1A, carboplatin, doxorubicin, paclitaxel, trastuzumab, or an mTOR inhibitor) depends on its half-life in the circulation, the condition of the patient and the route of administration among other factors. The frequency can be daily, weekly, monthly, quarterly, or at irregular intervals in response to changes in the patient's condition or

progression of the cancer being treated. An exemplary frequency for intravenous administration is between twice a week and quarterly over a continuous course of treatment, although more or less frequent dosing is also possible. Other exemplary frequencies for intravenous administration are between weekly or three out of every four weeks over a continuous course of treatment, although more or less frequent dosing is also possible. In an embodiment, one or both agents of the combination is administered once every three weeks. In another embodiment, one or both agents of the combination is administered once every four weeks. For subcutaneous administration, an exemplary dosing frequency is daily to monthly, although more or less frequent dosing is also possible.

[0048] The number of dosages of SGN-LIV1A administered depends on the nature of the cancer (e.g., whether presenting acute or chronic symptoms) and the response of the disorder to the treatment. For acute disorders or acute exacerbations of a chronic disorder between 1 and 10 doses are often sufficient. Sometimes a single bolus dose, optionally in divided form, is sufficient for an acute disorder or acute exacerbation of a chronic disorder. Treatment can be repeated for recurrence of an acute disorder or acute exacerbation. For chronic disorders, an antibody can be administered at regular intervals, e.g., weekly, fortnightly, monthly, quarterly, every six months for at least 1, 5 or 10 years, or the life of the patient.

[0049] Pharmaceutical compositions for parenteral administration of SGN-LIV1A are preferably sterile and substantially isotonic and manufactured under GMP conditions. Pharmaceutical compositions can be provided in unit dosage form (i.e., the dosage for a single administration). Pharmaceutical compositions can be formulated using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries. The formulation depends on the route of administration chosen. For injection, SGN-LIV1A can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline or acetate buffer (to reduce discomfort at the site of injection). The solution can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively SGN-LIV1A can be in lyophilized form for constitution with a suitable vehicle, e.g., sterile pyrogen-free

water, before use. The concentration of SGN-LIV1A in a liquid formulation can be e.g., 1-100 mg/ml, such as 10 mg/ml.

[0050] Treatment with the combination therapies of the invention can be further combined with additional chemotherapy, radiation, stem cell treatment, surgery other treatments effective against the disorder being treated. Useful classes of other agents that can be administered with the combination therapies of the invention include, for example, antibodies to other receptors expressed on cancerous cells, including other antibodies to the HER2 receptor (e.g., rastuzumab emtansine (KADCYLA®, Genentech, South San Francisco, CA), antitubulin agents (e.g., auristatins), pertuzumab (PERJETA®, Genentech, South San Francisco, CA)), or other antibody drug conjugates such as sacituzumab govitecan, checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1), DNA minor groove binders, DNA replication inhibitors, alkylating agents (e.g., platinum complexes such as *cis*-platin, mono(platinum), bis(platinum) and tri-nuclear platinum complexes and carboplatin), anthracyclines, antibiotics, antifolates, antimetabolites, chemotherapy sensitizers, duocarmycins, etoposides, fluorinated pyrimidines, ionophores, lexitropsins, nitrosoureas, platinols, pre-forming compounds, purine antimetabolites, puromycins, radiation sensitizers, steroids, taxanes, topoisomerase inhibitors, vinca alkaloids, and the like.

[0051] Treatment with the combination therapies of the invention can increase the median progression-free survival or overall survival time of patients with tumors (e.g., breast, prostate, melanoma), especially when relapsed or refractory, by at least 30% or 40% but preferably 50%, 60% to 70% or even 100% or longer, compared to the same treatment (e.g., chemotherapy) but without the combination therapies of the invention. In addition or alternatively, treatment (e.g., standard chemotherapy) including the combination therapies of the invention can increase the complete response rate, partial response rate, or objective response rate (complete + partial) of patients with tumors by at least 30% or 40% but preferably 50%, 60% to 70% or even 100% compared to the same treatment (e.g., chemotherapy) but without the combination therapies of the invention.

[0052] All patent filings, website, other publications, accession numbers and the like cited above or below are incorporated by reference in their entirety for all purposes to the same extent as if each individual item were specifically and individually indicated to be

so incorporated by reference. If different versions of a sequence are associated with an accession number at different times, the version associated with the accession number at the effective filing date of this application is meant. The effective filing date means the earlier of the actual filing date or filing date of a priority application referring to the accession number if applicable. Likewise if different versions of a publication, website or the like are published at different times, the version most recently published at the effective filing date of the application is meant unless otherwise indicated. Any feature, step, element, embodiment, or aspect of the invention can be used in combination with any other unless specifically indicated otherwise. Although the present invention has been described in some detail by way of illustration and example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

I. In vitro cytotoxicity assay and combination assays

Materials

[0053] Docetaxel, paclitaxel, doxorubicin, gemcitabine, and NVP-BEZ235 were purchased from LC Laboratories (Woburn, MA) and reconstituted in DMSO for in vitro assays. Cyclophosphamide was purchased from Selleckchem (Houston, TX). SGN-LIV1A was conjugated with average of 4 MMAE per antibody. US Patent No. 9,228,026 discloses further methods for the conjugation of vcMMAE to hLIV22.

Assays

[0054] MCF-7 (breast carcinoma) cells were obtained from ATCC. One day prior to assay, the MCF-7 cells were plated at a density of 2000 cells per well in 96-well plates, in Earles' Minimum Essential Media supplemented with 10% fetal bovine serum and 0.01 μ g/mL insulin.

[0055] The in vitro cytotoxicity assay was used to determine activity of each drug on MCF-7 cells. Briefly, cells were incubated with the indicated drugs at a titration of

concentrations for 120 hours. Viability of each drug was measured using Cell-titer Glo (Promega, Wisconsin) (Figure 1, top). In another assay, viability of SGN-LIV1A (hLIV22-vcMMAE) was also measured using Cell-titer Glo (Figure 1, bottom).

[0056] Combinations of SGN-LIV1A and one of the agents docetaxel, paclitaxel, doxorubicin, gemcitabine, NVP-BEZ235, everolimus, or cyclophosphomaide were added to cells the following day and kept in a 5% CO₂ incubator at 37°C for 120 hours. Cells were then lysed with Cell Titer Glo (Promega; Seattle, WA) for 60 minutes before viability was determined on an Envision plate reader (PerkinElmer; Waltham, MA).

[0057] To evaluate combination indexes (CI), SGN-LIV1A, doxorubicin, gemecitabine, and paclitaxel were combined at their ED50 concentrations or 2 fold higher or lower concentrations to obtain a 10 points dataset. The CI value was determined using CalcuSyn software (Biosoft; Cambridge, UK), which performs multiple drug dose-effect calculations using the Median Effect methods described by Chou and Talalay. *See* Chou TC (2010). Drug combination studies and their synergy quantification were performed using the Chou-Talalay method. *Cancer Res* 70: 440-446. Table 1 illustrates the results below:

Table 1: SGN-LIV1A Combinations

Drug/Combination	ED50	ED75	ED90	R values	Results
SGN-LIV1A				0.89	
Doxorubicin				0.85	
SGN-LIV1A + Doxorubicin	0.78	0.95	1.15	0.85	Moderate synergism to slight antagonism
Paclitaxel				0.82	
SGN-LIV1A + Paclitaxel	0.23	3.22	51.78	0.82	Strong synergism to very strong antagonism
Gemcitabine				0.81	
SGN-LIV1A + Gemcitabine	0.73	2.57	9.18	0.84	Moderate synergism to strong antagonism
SGN-LIV1A + Everolimus	0.58	0.56	0.55	0.96	Synergism

[0058] Table 1 and Figure 2 show that SGN-LIV1A and doxorubicin were moderately synergistic at their respective ED50 and ED75 concentrations (CI<1), and slightly antagonistic at their ED 90 concentrations. Table 1 and Figure 3 show that SGN-LIV1A and paclitaxel were strongly synergistic at the ED50 concentration, but antagonistic at

ED75 or ED90. Table 1 and Figure 4 show that SGN-LIV1A and gemcitabine were synergistic at the ED50 concentration, but not at the ED75 or ED90 concentrations. Table 1 and Figure 5 show that SGN-LIV1A and everolimus were synergistic at the ED50, ED75, and ED90 concentrations.

II. In vivo assays

[0059] NOD Scid Gamma (NSG) mice were obtained from Jackson Laboratory and implanted with 17-β-estradiol pellet (Innovative Research of America; Sarasota, FL) one day prior to cell implant. Five million MCF-7 cells were implanted subcutaneously with Matrigel (BD Biosciences; Franklin Lakes, NJ) and tumor volume was determined by a digital caliper twice a week, using the formula: volume= 1/2X length width².

[0060] Mice received treatments when the average tumor volume reached 100 mm³. The treatment regimen for each agent was: doxorubicin, 1mg/kg q4dx3 intravenous (IV); SGN-LIV1, 1 mg/kg q4dx4 intraperitoneal (IP); nab-paclitaxel (nanoparticle albumin-bound paclitaxel) 20 mg/kg q4dx3 IP; carboplatin 10 mg/kg q7dx3 IP; cyclophosphamide, 40 mg/kg q7dx3 IV; gemcitabine 20 mg/kg q7dx2 IP; and paclitaxel 10 mg/kg q3dx5 IP. Combination groups received the first dose of SGN-LIV1A and combination drug on the same day. n=6 for each group. The effects of each drug and their combination on tumor growth were plotted in Figures 6-8.

[0061] To determine the combined benefit in vivo, tumor growth inhibition (TGI) was compared using the area under the curve between untreated, single agent groups, and combined groups on the date the untreated animals were euthanized (Table 2). The following formula was used to calculate the TGI: $TGI=1-AUC_{drugx}/AUC_{untreated}$. Thus, the expected additive TGI for combination is $(1-TGI_{drug\ x})X(1-TGI_{drug\ y})$. When the TGI for the combination group is 10% greater than the expected TGI, the combination regimen is considered synergistic in vivo. The data in Table 2 shows that doxorubicin, 10 mg/kg nab-paclitaxel, and carboplatin provide the highest combinatorial benefit. Furthermore, the 20 mg/kg gemcitabine and 20 mg/kg nab-paclitaxel were found to be nearly additive when combined with SGN-LIV1A.

Table 2: Summary of In Vivo Tumor Growth Inhibition (TGI)

Dose		TGI	Expected combination TGI	Observed combination TGI	Combinatorial benefit
1 mg/kg	SGN-LIV1A	39%			
1 mg/kg	doxorubicin	26%	55%	75%	20%
20 mg/kg	nab-paclitaxel	75%	85%	87%	2%
10 mg/kg	nab-paclitaxel	23%	53%	62%	9%
10 mg/kg	carboplatin	21%	52%	60%	8%
40 mg/kg	cyclophosphamide	10%	45%	39%	-6%
20 mg/kg	gemcitabine	20%	51%	54%	3%

WHAT IS CLAIMED IS:

1. A method for treating a subject having or at risk of cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and a chemotherapeutic, wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E), and wherein the chemotherapeutic is one of carboplatin, doxorubicin, and paclitaxel.
2. The method of claim 1, wherein the subject has breast cancer.
3. The method of claim 2, wherein the breast cancer is triple negative breast cancer, triple positive breast cancer, HER2-positive breast cancer, or hormone receptor positive cancer.
4. The method of claim 3, wherein the subject has triple negative breast cancer.
5. The method of claim 1, wherein the subject has prostate cancer, ovarian cancer, endometrial cancer, pancreatic cancer, lung cancer, a cervical cancer, a melanoma, or squamous cell carcinoma.
6. The method of claim 1, wherein the LIV-1-ADC is administered at a dosage between 1.5 mg/kg and 4 mg/kg of the subject's body weight.
7. The method of claim 1, wherein the LIV-1-ADC is administered at a dosage of 2.5 mg/kg of the subject's body weight.
8. The method of claim 1, wherein the LIV-1-ADC is administered once every 3 weeks.
9. The method of claim 1, wherein the LIV-1-ADC is administered by intravenous injection.

10. The method of claim 1, wherein the chemotherapeutic is carboplatin, and wherein the carboplatin is administered at a dosage between 200 mg/m² and 750 mg/m².
11. The method of claim 1, wherein the chemotherapeutic is carboplatin, and wherein the carboplatin is administered by intravenous injection.
12. The method of claim 1, wherein the chemotherapeutic is doxorubicin, and wherein the doxorubicin is administered at a dosage between 40 mg/m² and 80 mg/m².
13. The method of claim 1, wherein the chemotherapeutic is doxorubicin, and wherein the doxorubicin is administered by intravenous injection.
14. The method of claim 1, wherein the chemotherapeutic is paclitaxel, and wherein the paclitaxel is administered at a dosage between 100 mg/m² to 260 mg/m².
15. The method of claim 1, wherein the chemotherapeutic is paclitaxel, and wherein the paclitaxel is administered by intravenous injection.
16. A method for treating a subject having or at risk of cancer, the method comprising administering to the subject a combination of carboplatin and a LIV-1 antibody drug conjugate (LIV-1-ADC), wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E), wherein the LIV-1-ADC is administered to the subject intravenously once every three weeks at a dosage of 2.5 mg/kg of the subject's body weight, and wherein the carboplatin is administered at a dosage of 300 mg/m².
17. A method for treating a subject having or at risk of cancer, the method comprising administering to the subject a combination of doxorubicin and a LIV-1 antibody drug conjugate (LIV-1-ADC), wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E), wherein the LIV-1-ADC is administered to the subject intravenously once every three weeks at a

dosage of 2.5 mg/kg of the subject's body weight, and wherein the doxorubicin is administered at a dosage of 60 mg/m².

18. A method for treating a subject having or at risk of cancer, the method comprising administering to the subject a combination of paclitaxel and a LIV-1 antibody drug conjugate (LIV-1-ADC), wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E), wherein the LIV-1-ADC is administered to the subject intravenously once every three weeks at a dosage of 2.5 mg/kg of the subject's body weight, and wherein the paclitaxel is administered at a dosage of 175 mg/m².

19. A method for treating a subject having or at risk of triple negative breast cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and a chemotherapeutic, wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E), and wherein the chemotherapeutic is one of carboplatin, doxorubicin, and paclitaxel.


20. A method for treating a subject having or at risk of cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and trastuzumab, wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E).

21. The method of claim 20, wherein the LIV-1-ADC is administered at a dosage between 0.5 mg/kg and 2.8 mg/kg of the subject's body weight.

22. The method of claim 20, wherein the LIV-1-ADC is administered at a dosage of 2.5 mg/kg of the subject's body weight.

23. The method of claim 20, wherein the LIV-1-ADC is administered once every 3 weeks.

24. The method of claim 20, wherein the trastuzumab is administered at an initial dose of 4 mg/kg of the subject's body weight over a 90 minute IV infusion, then 2 mg/kg of the subject's body weight over a 30 minute IV infusion.
25. The method of claim 20, wherein the trastuzumab is administered at an initial dose of 8 mg/kg of the subject's body weight over a 90 minute IV infusion, then 6 mg/kg of the subject's body weight over a 30 to 90 minute IV infusion.
27. A method for treating a subject having or at risk of cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and trastuzumab emtansine, wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E).
28. A method for treating a subject having or at risk of cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and pertuzumab, wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E).
29. A method for treating a subject having or at risk of cancer, the method comprising administering to the subject a LIV-1 antibody drug conjugate (LIV-1-ADC) and a checkpoint inhibitor, wherein the LIV-1-ADC comprises a humanized hLIV22 antibody conjugated to a vcMMAE (valine-citrulline-monomethyl auristatin E).
30. The method of claim 29, wherein the checkpoint inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, B7-DC-Fc, LAG3, or TIM3.

**FIGURE 1**






FIGURE 2

**FIGURE 3**







FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8

0710-00313PC_Sequence_Listing_ST25
SEQUENCE LISTING

<110> Seattle Genetics, Inc.
Sussman, Django
Li, Fu
Kostic, Ana
<120> Combination Therapy Using a LIV1-ADC and a Chemotherapeutic
<130> 0710-00313PC
<150> US 62/308,639
<151> 2016-03-15
<150> US 62/317,792
<151> 2016-04-04
<150> US 62/367,510
<151> 2016-07-27
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 755
<212> PRT
<213> Homo sapiens
<400> 1

Met Ala Arg Lys Leu Ser Val Ile Leu Ile Leu Thr Phe Ala Leu Ser
1 5 10 15

Val Thr Asn Pro Leu His Glu Leu Lys Ala Ala Ala Phe Pro Gln Thr
20 25 30

Thr Glu Lys Ile Ser Pro Asn Trp Glu Ser Gly Ile Asn Val Asp Leu
35 40 45

Ala Ile Ser Thr Arg Gln Tyr His Leu Gln Gln Leu Phe Tyr Arg Tyr
50 55 60

Gly Glu Asn Asn Ser Leu Ser Val Glu Gly Phe Arg Lys Leu Leu Gln
65 70 75 80

Asn Ile Gly Ile Asp Lys Ile Lys Arg Ile His Ile His His Asp His
85 90 95

Asp His His Ser Asp His Glu His His Ser Asp His Glu Arg His Ser
100 105 110

Asp His Glu His His Ser Glu His Glu His His Ser Asp His Asp His
115 120 125

His Ser His His Asn His Ala Ala Ser Gly Lys Asn Lys Arg Lys Ala
130 135 140

Leu Cys Pro Asp His Asp Ser Asp Ser Ser Gly Lys Asp Pro Arg Asn
Page 1

145

150

155

160

Ser Gln Gly Lys Gly Ala His Arg Pro Glu His Ala Ser Gly Arg Arg
165 170 175

Asn Val Lys Asp Ser Val Ser Ala Ser Glu Val Thr Ser Thr Val Tyr
180 185 190

Asn Thr Val Ser Glu Gly Thr His Phe Leu Glu Thr Ile Glu Thr Pro
195 200 205

Arg Pro Gly Lys Leu Phe Pro Lys Asp Val Ser Ser Ser Thr Pro Pro
210 215 220

Ser Val Thr Ser Lys Ser Arg Val Ser Arg Leu Ala Gly Arg Lys Thr
225 230 235 240

Asn Glu Ser Val Ser Glu Pro Arg Lys Gly Phe Met Tyr Ser Arg Asn
245 250 255

Thr Asn Glu Asn Pro Gln Glu Cys Phe Asn Ala Ser Lys Leu Leu Thr
260 265 270

Ser His Gly Met Gly Ile Gln Val Pro Leu Asn Ala Thr Glu Phe Asn
275 280 285

Tyr Leu Cys Pro Ala Ile Ile Asn Gln Ile Asp Ala Arg Ser Cys Leu
290 295 300

Ile His Thr Ser Glu Lys Lys Ala Glu Ile Pro Pro Lys Thr Tyr Ser
305 310 315 320

Leu Gln Ile Ala Trp Val Gly Gly Phe Ile Ala Ile Ser Ile Ile Ser
325 330 335

Phe Leu Ser Leu Leu Gly Val Ile Leu Val Pro Leu Met Asn Arg Val
340 345 350

Phe Phe Lys Phe Leu Leu Ser Phe Leu Val Ala Leu Ala Val Gly Thr
355 360 365

Leu Ser Gly Asp Ala Phe Leu His Leu Leu Pro His Ser His Ala Ser
370 375 380

His His His Ser His Ser His Glu Glu Pro Ala Met Glu Met Lys Arg
385 390 395 400

Gly Pro Leu Phe Ser His Leu Ser Ser Gln Asn Ile Glu Glu Ser Ala
405 410 415

Tyr Phe Asp Ser Thr Trp Lys Gly Leu Thr Ala Leu Gly Gly Leu Tyr
Page 2

0710-00313PC_Sequence_Listing_ST25
420 425 430

Phe Met Phe Leu Val Glu His Val Leu Thr Leu Ile Lys Gln Phe Lys
435 440 445

Asp Lys Lys Lys Lys Asn Gln Lys Lys Pro Glu Asn Asp Asp Asp Val
450 455 460

Glu Ile Lys Lys Gln Leu Ser Lys Tyr Glu Ser Gln Leu Ser Thr Asn
465 470 475 480

Glu Glu Lys Val Asp Thr Asp Asp Arg Thr Glu Gly Tyr Leu Arg Ala
485 490 495

Asp Ser Gln Glu Pro Ser His Phe Asp Ser Gln Gln Pro Ala Val Leu
500 505 510

Glu Glu Glu Glu Val Met Ile Ala His Ala His Pro Gln Glu Val Tyr
515 520 525

Asn Glu Tyr Val Pro Arg Gly Cys Lys Asn Lys Cys His Ser His Phe
530 535 540

His Asp Thr Leu Gly Gln Ser Asp Asp Leu Ile His His His His Asp
545 550 555 560

Tyr His His Ile Leu His His His His His Gln Asn His His Pro His
565 570 575

Ser His Ser Gln Arg Tyr Ser Arg Glu Glu Leu Lys Asp Ala Gly Val
580 585 590

Ala Thr Leu Ala Trp Met Val Ile Met Gly Asp Gly Leu His Asn Phe
595 600 605

Ser Asp Gly Leu Ala Ile Gly Ala Ala Phe Thr Glu Gly Leu Ser Ser
610 615 620

Gly Leu Ser Thr Ser Val Ala Val Phe Cys His Glu Leu Pro His Glu
625 630 635 640

Leu Gly Asp Phe Ala Val Leu Leu Lys Ala Gly Met Thr Val Lys Gln
645 650 655

Ala Val Leu Tyr Asn Ala Leu Ser Ala Met Leu Ala Tyr Leu Gly Met
660 665 670

Ala Thr Gly Ile Phe Ile Gly His Tyr Ala Glu Asn Val Ser Met Trp
675 680 685

Ile Phe Ala Leu Thr Ala Gly Leu Phe Met Tyr Val Ala Leu Val Asp
Page 3

0710-00313PC_Sequence_Listing_ST25
690 695 700

Met Val Pro Glu Met Leu His Asn Asp Ala Ser Asp His Gly Cys Ser
705 710 715 720

Arg Trp Gly Tyr Phe Phe Leu Gln Asn Ala Gly Met Leu Leu Gly Phe
725 730 735

Gly Ile Met Leu Leu Ile Ser Ile Phe Glu His Lys Ile Val Phe Arg
740 745 750

Ile Asn Phe
755

<210> 2
<211> 749
<212> PRT
<213> Homo sapiens

<400> 2

Met Ala Arg Lys Leu Ser Val Ile Leu Ile Leu Thr Phe Ala Leu Ser
1 5 10 15

Val Thr Asn Pro Leu His Glu Leu Lys Ala Ala Ala Phe Pro Gln Thr
20 25 30

Thr Glu Lys Ile Ser Pro Asn Trp Glu Ser Gly Ile Asn Val Asp Leu
35 40 45

Ala Ile Ser Thr Arg Gln Tyr His Leu Gln Gln Leu Phe Tyr Arg Tyr
50 55 60

Gly Glu Asn Asn Ser Leu Ser Val Glu Gly Phe Arg Lys Leu Leu Gln
65 70 75 80

Asn Ile Gly Ile Asp Lys Ile Lys Arg Ile His Ile His His Asp His
85 90 95

Asp His His Ser Asp His His Ser Asp His Glu Arg His Ser
100 105 110

Asp His Glu His His Ser Asp His Glu His His Ser Asp His Asn His
115 120 125

Ala Ala Ser Gly Lys Asn Lys Arg Lys Ala Leu Cys Pro Asp His Asp
130 135 140

Ser Asp Ser Ser Gly Lys Asp Pro Arg Asn Ser Gln Gly Lys Gly Ala
145 150 155 160

His Arg Pro Glu His Ala Ser Gly Arg Arg Asn Val Lys Asp Ser Val
165 170 175

0710-00313PC_Sequence_Listing_ST25

Ser Ala Ser Glu Val Thr Ser Thr Val Tyr Asn Thr Val Ser Glu Gly
180 185 190

Thr His Phe Leu Glu Thr Ile Glu Thr Pro Arg Pro Gly Lys Leu Phe
195 200 205

Pro Lys Asp Val Ser Ser Ser Thr Pro Pro Ser Val Thr Ser Lys Ser
210 215 220

Arg Val Ser Arg Leu Ala Gly Arg Lys Thr Asn Glu Ser Val Ser Glu
225 230 235 240

Pro Arg Lys Gly Phe Met Tyr Ser Arg Asn Thr Asn Glu Asn Pro Gln
245 250 255

Glu Cys Phe Asn Ala Ser Lys Leu Leu Thr Ser His Gly Met Gly Ile
260 265 270

Gln Val Pro Leu Asn Ala Thr Glu Phe Asn Tyr Leu Cys Pro Ala Ile
275 280 285

Ile Asn Gln Ile Asp Ala Arg Ser Cys Leu Ile His Thr Ser Glu Lys
290 295 300

Lys Ala Glu Ile Pro Pro Lys Thr Tyr Ser Leu Gln Ile Ala Trp Val
305 310 315 320

Gly Gly Phe Ile Ala Ile Ser Ile Ile Ser Phe Leu Ser Leu Leu Gly
325 330 335

Val Ile Leu Val Pro Leu Met Asn Arg Val Phe Phe Lys Phe Leu Leu
340 345 350

Ser Phe Leu Val Ala Leu Ala Val Gly Thr Leu Ser Gly Asp Ala Phe
355 360 365

Leu His Leu Leu Pro His Ser His Ala Ser His His Ser His Ser
370 375 380

His Glu Glu Pro Ala Met Glu Met Lys Arg Gly Pro Leu Phe Ser His
385 390 395 400

Leu Ser Ser Gln Asn Ile Glu Glu Ser Ala Tyr Phe Asp Ser Thr Trp
405 410 415

Lys Gly Leu Thr Ala Leu Gly Gly Leu Tyr Phe Met Phe Leu Val Glu
420 425 430

His Val Leu Thr Leu Ile Lys Gln Phe Lys Asp Lys Lys Lys Lys Asn
435 440 445

0710-00313PC_Sequence_Listing_ST25

Gln Lys Lys Pro Glu Asn Asp Asp Asp Val Glu Ile Lys Lys Gln Leu
450 455 460

Ser Lys Tyr Glu Ser Gln Leu Ser Thr Asn Glu Glu Lys Val Asp Thr
465 470 475 480

Asp Asp Arg Thr Glu Gly Tyr Leu Arg Ala Asp Ser Gln Glu Pro Ser
485 490 495

His Phe Asp Ser Gln Gln Pro Ala Val Leu Glu Glu Glu Val Met
500 505 510

Ile Ala His Ala His Pro Gln Glu Val Tyr Asn Glu Tyr Val Pro Arg
515 520 525

Gly Cys Lys Asn Lys Cys His Ser His Phe His Asp Thr Leu Gly Gln
530 535 540

Ser Asp Asp Leu Ile His His His His Asp Tyr His His Ile Leu His
545 550 555 560

His His His His Gln Asn His His Pro His Ser His Ser Gln Arg Tyr
565 570 575

Ser Arg Glu Glu Leu Lys Asp Ala Gly Val Ala Thr Leu Ala Trp Met
580 585 590

Val Ile Met Gly Asp Gly Leu His Asn Phe Ser Asp Gly Leu Ala Ile
595 600 605

Gly Ala Ala Phe Thr Glu Gly Leu Ser Ser Gly Leu Ser Thr Ser Val
610 615 620

Ala Val Phe Cys His Glu Leu Pro His Glu Leu Gly Asp Phe Ala Val
625 630 635 640

Leu Leu Lys Ala Gly Met Thr Val Lys Gln Ala Val Leu Tyr Asn Ala
645 650 655

Leu Ser Ala Met Leu Ala Tyr Leu Gly Met Ala Thr Gly Ile Phe Ile
660 665 670

Gly His Tyr Ala Glu Asn Val Ser Met Trp Ile Phe Ala Leu Thr Ala
675 680 685

Gly Leu Phe Met Tyr Val Ala Leu Val Asp Met Val Pro Glu Met Leu
690 695 700

His Asn Asp Ala Ser Asp His Gly Cys Ser Arg Trp Gly Tyr Phe Phe
705 710 715 720

0710-00313PC_Sequence_Listing_ST25

Leu Gln Asn Ala Gly Met Leu Leu Gly Phe Gly Ile Met Leu Leu Ile
725 730 735

Ser Ile Phe Glu His Lys Ile Val Phe Arg Ile Asn Phe
740 745

<210> 3
<211> 113
<212> PRT
<213> Artificial Sequence

<220>
<223> Light chain variable region of hLIV22

<400> 3

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1 5 10 15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
20 25 30

Ser Gly Asn Thr Tyr Leu Glu Trp Tyr Gln Gln Arg Pro Gly Gln Ser
35 40 45

Pro Arg Pro Leu Ile Tyr Lys Ile Ser Thr Arg Phe Ser Gly Val Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly
85 90 95

Ser His Val Pro Tyr Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
100 105 110

Arg

<210> 4
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> Heavy chain variable region of hLIV22

<400> 4

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Leu Thr Ile Glu Asp Tyr
20 25 30

0710-00313PC_Sequence_Listing_ST25

Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Gly Pro Lys Phe
50 55 60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Asn Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Val His Asn Ala His Tyr Gly Thr Trp Phe Ala Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120